4
Changes in Ownership
Denali Therapeutics Inc. Filed Acc 0001714899-22-000035
President and CEO sold 2,719 shares at $37.55 ($102,104)
- President and CEO acquired 70,749 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
Table I: Non-derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Watts Ryan J. President and CEO | 2022-02-09 | Sale | −2,719 | $37.55 | $102,104 | 2,119,442 | I: show line 1 in the form |
| Watts Ryan J. President and CEO | 2022-02-10 | Option exercise | +64,631 | $5.28 | $341,252 | 254,522 | D: show line 2 in the form |
| Watts Ryan J. President and CEO | 2022-02-10 | Option exercise | +6,118 | $9.60 | $58,733 | 260,640 | D: show line 3 in the form |
| Open-market sales · 2,719 sh · avg $37.55 · $102,104 | |||||||
Table II: Derivative
| Insider | Date | Transaction | Shares | Price | Value | Exercise | Expires | Underlying | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|
| Watts Ryan J. President and CEO | 2022-02-10 | Option exercise · Stock Option (right to buy) | −64,631 | 0 | D: show line 4 in the form | |||||
| Watts Ryan J. President and CEO | 2022-02-10 | Option exercise · Stock Option (right to buy) | −6,118 | 0 | D: show line 5 in the form |
Loading xslF345X03/wf-form4_164461792855991.xml…